Literature DB >> 2360792

Mechanism of muscle wasting in myotonic dystrophy.

R C Griggs1, R Jozefowicz, W Kingston, K S Nair, B E Herr, D Halliday.   

Abstract

Myotonic dystrophy is associated with progressive muscular atrophy. In order to determine the mechanism of muscle wasting in this condition, we measured fractional mixed skeletal muscle protein synthesis in the postabsorptive state in 8 patients with myotonic dystrophy, and compared the results with those of 10 normal subjects. Fractional muscle protein synthesis was determined by measuring the increment of 13C leucine in mixed skeletal muscle protein obtained by needle biopsy from the quadriceps muscle during a primed-continuous infusion of L-(1-13C) leucine. We used plasma 13C alpha-ketoisocaproate (representing intracellular leucine labeling) as the precursor pool for the calculation of fractional muscle protein synthesis and leucine kinetics. Fractional muscle protein synthesis was depressed in the patients with myotonic dystrophy (28% decrease, p less than 0.02). Leucine flux, leucine oxidation, and the nonoxidative portion of leucine flux were not different between the patients with myotonic dystrophy and the normal control subjects. Muscle atrophy in myotonic dystrophy reflects a selective decrease in muscle protein synthesis without any similar decrease in nonmuscle protein synthesis. This decrease may result from an impaired end-organ response to anabolic hormones or substrates.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2360792     DOI: 10.1002/ana.410270509

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  6 in total

1.  Reexpression of pyruvate kinase M2 in type 1 myofibers correlates with altered glucose metabolism in myotonic dystrophy.

Authors:  Zhihua Gao; Thomas A Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-30       Impact factor: 11.205

2.  Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1.

Authors:  Chad R Heatwole; Katy J Eichinger; Deborah I Friedman; James E Hilbert; Carlayne E Jackson; Eric L Logigian; William B Martens; Michael P McDermott; Shree K Pandya; Christine Quinn; Alexis M Smirnow; Charles A Thornton; Richard T Moxley
Journal:  Arch Neurol       Date:  2010-09-13

3.  Expanded CUG repeat RNAs form hairpins that activate the double-stranded RNA-dependent protein kinase PKR.

Authors:  B Tian; R J White; T Xia; S Welle; D H Turner; M B Mathews; C A Thornton
Journal:  RNA       Date:  2000-01       Impact factor: 4.942

4.  Alternative splicing of RyR1 alters the efficacy of skeletal EC coupling.

Authors:  Takashi Kimura; John D Lueck; Peta J Harvey; Suzy M Pace; Noriaki Ikemoto; Marco G Casarotto; Robert T Dirksen; Angela F Dulhunty
Journal:  Cell Calcium       Date:  2009-01-07       Impact factor: 6.817

Review 5.  Myotonic dystrophy: therapeutic strategies for the future.

Authors:  Thurman M Wheeler
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

6.  Aberrant insulin receptor expression is associated with insulin resistance and skeletal muscle atrophy in myotonic dystrophies.

Authors:  Laura Valentina Renna; Francesca Bosè; Elisa Brigonzi; Barbara Fossati; Giovanni Meola; Rosanna Cardani
Journal:  PLoS One       Date:  2019-03-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.